Pixium Vision Is Setting its Sights on Finding a Buyer

2023-10-23
并购
Pixium Vision is looking for a buyer a little more than two years after ending a deal to acquire Second Sight Medical Products.
Last week, the Paris, France-based company and maker of bionic eye implants announced the launch of a process to find buyers. The company said it was undertaking this measure because it could not find financial investors within the restricted timeframe and in line with its needs.
The company said the deadline for submission of offers has been set by the court-appointed administrators to November 20, 2023 at 12:00 p.m.
Earlier this year, Pixium won breakthrough device designation for the Prima System, an implant to help treat dry age-related macular degeneration.
The designation came at a time when Pixium was well-removed from a merger attempt with Second Sight Medical Products. Pixium terminated plans to acquire the Second Sight company because the Sylmar, CA-based company filed for a private placement of $27.9 million. Pixium noted that placement violated the memorandum of understanding between the two.
Second Sight would go on to merge with Nano Precision Medical to be rebranded as Vivani Medical.
About a year after the merger plans were put on halt, a Paris Commercial Court ordered the merged company to pay Pixium $1.68 million for violating the MoU.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
靶点
-
药物
-
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI,赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台,以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。